Simufilam (PTI-125)

About Cassava Sciences

Cassava Sciences is a mission-driven biotech focused on developing transformative treatments for Alzheimer's disease, a market with profound unmet need. Its core strategy is built on a unique scientific platform targeting altered filamin A (FLNA) protein to stabilize disease pathology. The company's primary achievement is the advancement of its lead drug, simufilam, into two large, global Phase 3 efficacy and safety trials. Cassava's strategy hinges on successfully demonstrating simufilam's clinical benefit to secure regulatory approval and address a multi-billion dollar market.

About Cassava Sciences

Cassava Sciences is a mission-driven biotech focused on developing transformative treatments for Alzheimer's disease, a market with profound unmet need. Its core strategy is built on a unique scientific platform targeting altered filamin A (FLNA) protein to stabilize disease pathology. The company's primary achievement is the advancement of its lead drug, simufilam, into two large, global Phase 3 efficacy and safety trials. Cassava's strategy hinges on successfully demonstrating simufilam's clinical benefit to secure regulatory approval and address a multi-billion dollar market.

Therapeutic Areas